Erlotinib

Erlotinib plus cisplatin-based chemoradiation promising for cervical cancer

Erlotinib plus cisplatin-based chemoradiation promising for cervical cancer

Treatment with epidermal growth factor receptor inhibitor erlotinib combined with cisplatin-based chemoradiation seems safe and effective for locally advanced cervical cancer, according to a study.

Erlotinib doesn't hurt but doesn't help standard head-and-neck therapy

Adding erlotinib did not increase treatment toxicity in squamous cell carcinoma of the head and neck, but it also did not improve survival.

Targeted treatment of resistant cancer may improve progression-free survival with some drugs

By

Pockets of resistant cancer can be treated with focused, targeted radiation while continuing chemotherapy with the targeted drugs crizotinib or erlotinib.

Veristrat predicts response but not survival benefit from NSCLC treatment

By

The plasma test VeriStrat can predict response but not survival benefit from erlotinib in patients with advanced non-small cell lung cancer (NSCLC).

New tool reveals individual tumor cell reactions to therapy

Time-lapse imaging, analytical tools, and software are combined to provide a detailed picture of a single tumor cell's response to a cancer drug.

Study demonstrates cost-effectiveness of erlotinib treatment

By

Erlotinib is a marginally cost-effective treatment for patients with advanced non-small cell lung cancer, according to the results of an economic analysis published in the Journal of the National Cancer Institute (2010;102(5):298-306).

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs